A single-centre experience of post-renal transplant lymphoproliferative disorder
A single-centre experience of post-renal transplant lymphoproliferative disorder
复制标题
DOI：
10.1007/s00147-003-0596-0
复制
发表时间：
2003-07-01
影响因子：
3.1
通讯作者：
Johnson, DW
中科院分区：
文献类型：
--
作者：
Herzig, KA;Juffs, HG;Johnson, DW
移植后淋巴组织增生性疾病（PTLD）占所有移植的1 - 10%。以前的PTLD临床病理学研究受到数量少、随访时间短、数据过时、合并实体器官移植结果的异质性以及选择性纳入早发性疾病的限制。因此，我们在这里进行回顾性分析，并确定所有的PTLD的情况下，复杂的肾移植在亚历山德拉公主医院1969年6月30日至2001年5月31日。随后取出肿瘤样本进行病理学检查和EB病毒编码的RNA原位杂交（EBER-ISH）。在2,030例肾移植患者中，29例（1.4%）在中位时间0.5年（范围0.1 - 23.3年）后发生PTLD。PTLD患者更有可能接受环孢霉素治疗（76%对62%，P
Post-transplant lymphoproliferative disorder (PTLD) complicates 1 to 10% of all transplantations. Previous clinicopathological studies of PTLD have been limited by small numbers, short follow-up times, outdated data, heterogeneity of pooled solid-organ transplant results, and selective inclusion of early-onset disease. We therefore undertake here a retrospective analysis and identify all cases of PTLD that complicated renal transplantation at the Princess Alexandra Hospital between 30 June 1969 and 31 May 2001. Tumour samples were subsequently retrieved for pathological review and for Epstein-Barr virus-encoded RNA in situ hybridisation (EBER-ISH). Of 2,030 renal transplantation patients, 29 (1.4%) developed PTLD after a median period of 0.5 years (range 0.1 to 23.3 years). PTLD patients were more likely to have received cyclosporine (76% versus 62%, P